Mucosat solution for intramuscular injection of an ampoule 1 ml 10 pcs

Chondroitin sulfate

1 ml of solution contains: Active substance: chondroitin sodium sulfate 100 mg. Auxiliary substances: benzyl alcohol - 9 mg, water d / and - up to 1 ml.

The drug has chondroprotective, stimulating the regeneration of cartilage tissue, anti-inflammatory action. Participates in the construction of the main substance of cartilage and bone tissue, improves phosphorus-calcium metabolism in cartilage tissue, inhibits enzymes that violate the structure and function of articular cartilage, inhibits the processes of cartilage tissue degeneration. Stimulates the synthesis of proteoglycans, normalizes the metabolism of hyaline cartilage, contributes to the regeneration of cartilage surfaces and articular bags. It prevents compression of the connective tissue, increases the production of synovial fluid and mobility of the affected joints, reduces concomitant inflammation, soreness, and reduces the need for NSAIDs. In degenerative changes, the cartilage tissue is a means of replacement therapy. The therapeutic effect persists for a long time (3-6 months) after the end of the course of treatment.

The absorption of chondroitin sodium sulfate is easily absorbed after intramuscular injection. After 30 minutes, it is found in the blood in significant concentrations: the maximum concentration is reached after 1 hour, then its content gradually decreases over 2 days. Distribution of Chondroitin sodium sulfate accumulates mainly in the cartilage tissue. The synovium is not an obstacle to its penetration into the joint cavity. Fifteen minutes after the intramuscular injection of chondroitin, sodium sulfate is found in the synovial fluid, then it enters the articular cartilage, where its content reaches a maximum after 48 hours.

Mucosate is prescribed for the treatment of degenerative-dystrophic diseases of the spine and joints (in case of primary arthrosis, osteoarthrosis with damage to large joints, intervertebral osteoarthrosis), in fractures, osteoporosis, and periodontal diseases. Mucosat is effective in the postoperative period of patients undergoing joint surgery.

Hypersensitivity to the drug. The tendency to bleeding. Thrombophlebitis.

Currently, data on the use of the drug "Mukosat" during pregnancy and lactation, as well as in children are not available.

Dosage and administration

The drug is administered intramuscularly in 1 ml every other day. With good tolerance, the dose is increased to 2 ml, starting with the fourth injection. The treatment course is 25-30 injections. If necessary, repeat courses are possible after 6 months.

Allergic reactions and hemorrhages at the injection site are possible (in these cases, the drug is canceled).

Data overdose is not provided.

With caution should be prescribed the drug Mucosat simultaneously with direct-acting anticoagulants. It is also possible to enhance the effect of indirect anticoagulants, antiplatelet agents and fibrinolytics.